Media
-
CPHI North America was a success for Ami Lifesciences Pvt Ltd. We appreciate our clients and guests stopping
April 25 to 27, 2023.
-
We are exhibiting at CPHI North America, and you are welcome to visit the Ami Lifesciences
April 25 to 27, 2023.
-
We are pleased to inform that we are now EcoVadis Certified, the most widely recognized international
20 April 2023
-
We are excited to be at CPhI Japan (19-21 April 2023). It will be a pleasure to meet our customers
10 April 2023
-
We will be exhibiting at the CPHI North America Exhibition in Pennsylvania from April 25th to 27th, 2023.
10 April 2023
-
The USDMF for Empagliflozin API submitted to the USFDA. Our expert team created and scaled up a lean process to assist our formulation partners
27 Mar 2023
-
Ami Lifesciences had a very successful DCAT Week, with significant customer meetings and anticipating an incredible path forward.
27 Mar 2023
-
We are pleased to inform you that the USDMF for Edoxaban API has been submitted to the USFDA. Based on our process expertise
27 Mar 2023
-
Mr Varad Nabar, AVP Marketing, will attend DCAT (Drug, Chemical & Associated Technologies Association) Week 2023 in New York
20 - 23 Mar 2023
-
The DCAT (Drug, Chemical & Associated Technologies Association) week is approaching; come meet us and learn more about Ami Lifesciences
20 - 23 Mar 2023
-
Our CEO, Amit Kaptain, will be in New York from March 20th to 23rd for DCAT (Drug, Chemical & Associated Technologies Association) Week 2023.
20 - 23 Mar 2023
-
It gives us great pleasure to announce that the USDMF for Sacubitril Sodium has been submitted to the USFDA. With an innovative development strategy, our team of experts
20 Mar 2023
-
Our innovation efforts have been validated today when our R&D team received Excellence in Research and Development" award.
20 Mar 2023
-
We are pleased to inform you that Sacubitril Valsartan's USDMF has been successfully submitted to the USFDA. Our process experts developed Sacubitril Valsartan
09 Mar 2023
-
We are pleased to announce that the USDMF for Desvenlafaxine Succinate has been submitted to the USFDA.
08 Mar 2023
-
We are glad to share that the US DMF for Sevelamer Hydrochloride was successfully submitted to the USFDA. We have a distinctive advantage
02 Mar 2023
-
We are happy to announce our USDMF filing of Dapagliflozin Amorphous to the USFDA.
02 Mar 2023
-
We are extremely happy to share the successful filling of Febuxostat USDMF with the USFDA.
18 Feb 2023
-
We are happy to share that the US DMF for Sevelamer Carbonate was successfully submitted to the USFDA.
17 Feb 2023
-
We are delighted to announce that the USDMF for Tadalafil was successfully submitted to the USFDA.
17 Feb 2023
